ArticleOrphanet journal of rare diseases2022

The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis.

Enrico Costa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.